NY-BEHAVOX
Behavox , the world’s only AI-based data operating platform used by firms to catch misconduct before it causes massive regulatory fines and company crises, announced today it has expanded its global operations into the Nordic market, appointing Christopher Sander as Nordics’ Regional Director.
"Risk, threats, and misconduct come from different places and speak different languages, so Behavox is proud to bring our vast customer experience as a trusted regulatory expert to help Nordic clients protect and preserve the integrity of their operations,” said Erkin Adylov, Founder and CEO of Behavox. "By accelerating our investment in the region to serve its finance and enterprise industries, Behavox is broadening its ongoing commitment to helping more and more firms identify misconduct quickly and precisely."
Behavox's Nordics expansion follows its announcement earlier this week that Danske Bank A/S , Denmark’s largest, full-service bank, has successfully implemented Behavox’s solution for compliance supervision in just four months. In June, Danske Bank partnered with Behavox to implement its Compliance solution. Since then, Behavox has helped the bank become faster, smarter, and more agile in supporting employees as they service millions of customers.
Behavox has vast customer experience successfully implementing the largest, most complex multilingual projects in the financial services sector – from the world’s biggest multinational banks to the most prominent hedge funds and private equity firms. Danske Bank represents one of these projects, making the SaaS-based deployment a major achievement for the firm and Behavox alike.
Sander's background as a global business leader includes extensive experience at Dropbox, most recently as their Head of the Nordics, where he led one of the organization's most profitable European regions. Prior to this role, Sander acted as Dropbox’s Chief of Staff and proxy to the European Senior Leadership Team.
"The ability of Behavox’s solution to provide multilingual coverage of compliance requirements across numerous communications applications in multiple markets is important for leading Nordic firms," Sander said. "I'm excited to help Behavox grow its European presence and enable clients to uncover risk quickly and accurately before it results in compliance violations that cause a nightmare scenario of reputational and financial consequences."
Behavox’s expansion into the Nordics is just one of the latest corporate developments for the fast-growing AI company. Today the company also announced additional operations in Tokyo, Japan . In September, Behavox announced the appointment of Microsoft (NASDAQ: MSFT) veteran Gagan Gulati as the company’s first Chief Product Officer . In the Summer, Behavox expanded its presence in Montréal, Québec, with a long-term, lease commitment to accommodate continued hiring of engineering, data science, and product development teams.
Find current job openings at Behavox
Read about the latest Behavox announcements and news coverage
Read about the latest industry trends through the Behavox blog
About Behavox Ltd.
Behavox is the gold standard for enterprise risk and compliance solutions. Its AI-powered technology helps global banks, hedge funds, and private equity firms identify bad actors quickly and accurately, preventing massive fines and company-debilitating crises. Behavox solutions uncover financial regulatory misconduct like insider trading, collusion, and market manipulation as well as HR-related misconduct, such as racism, sexual harassment, and discrimination. As an award-winning team of innovators and industry experts, Behavox has a reputation for successfully implementing the largest, most complex, global projects in the market. Customers rely on Behavox as an indispensable extension of their teams. They depend on Behavox to protect the integrity of their operations and preserve the trust of their clients. Founded in 2014, Behavox is headquartered in New York City and has offices in Montreal, San Francisco, Seattle, Singapore, Tokyo, London, and Abu Dhabi. More information about the company is available at www.behavox.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005662/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom